Granite Point Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Granite Point Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-579	Closed	-$1.01M	–	88
2014 Q2	$1.01M	Sell	579 -60	-9%	-$92.1K	0.7%	32
2014 Q1	$1.32M	Buy	+639	New	+$1.5M	0.94%	27

Other funds holding GLMD

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Granite Point Capital Management's GLMD Position: Q3 2014 in Review

Granite Point Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2014, closing a stake of 579 shares — an estimated $1.01M sold.

Granite Point Capital Management first reported a position in GLMD in Q1 2014 and held it in 2 quarters. The position peaked at $1.32M in Q1 2014. 19 funds tracked by Wall St. Rank hold GLMD as of Q3 2014.

Granite Point Capital Management reported no remaining Galmed Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Granite Point Capital Management sold 579 Galmed Pharmaceuticals shares in Q3 2014, an estimated $1.01M.
Granite Point Capital Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 2 quarters.
Granite Point Capital Management's Galmed Pharmaceuticals position peaked at $1.32M in Q1 2014.
19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2014.

Based on Granite Point Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.